<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079896</url>
  </required_header>
  <id_info>
    <org_study_id>SNOXH94C301</org_study_id>
    <secondary_id>2013-003585-14</secondary_id>
    <nct_id>NCT02079896</nct_id>
  </id_info>
  <brief_title>Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients</brief_title>
  <official_title>Safety, PK/PD, and Efficacy of NOX-H94 in Dialysis Patients With ESA-hyporesponsive Anemia: A Randomized, Double Blind, Placebo Controlled Parallel Group Study With a Single Blind Cross-over Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NOXXON Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NOXXON Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dialysis patients regularly suffer from anemia which may be caused by various contributing
      factors, alone or in combination, including blood loss, low erythropoietin and iron
      sequestration. In most patients, the anemia is responsive to treatment with erythropoietin or
      other erythropoiesis stimulating agents (ESA) alone or in combination with intravenous (i.v.)
      iron. In about 10% of patients however, the anaemia does not respond appropriately to this
      standard treatment and high to very high doses of ESA and i.v. iron are used to maintain
      acceptable hemoglobin concentrations. In these patients, hepcidin was identified as a
      causative factor leading to anemia of chronic disease with functional iron deficiency and
      ESA-hyporesponsiveness.

      The Spiegelmer lexaptepid pegol (NOX-H94) offers a hepcidin-specific approach to the
      treatment of anemia of chronic disease. The safety and the activity of lexaptepid pegol are
      supported by data from healthy subjects and patients with multiple myeloma or lymphoma. The
      present study in dialysis patients with functional iron deficiency and ESA-hyporesponsiveness
      is conducted to demonstrate the safety of lexaptepid pegol in this population, to investigate
      its pharmacokinetic (PK) and pharmacodynamic (PD) profiles and its efficacy in increasing
      haemoglobin (Hb) in dialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>up to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Weeks 1, 2, 3, 4, 5, 6, 8</time_frame>
    <description>Peak concentrations, systemic exposure, elimination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>Change in serum iron concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Weeks 1, 2, 3, 4, 5, 6, 8</time_frame>
    <description>Change in hemoglobin</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Anemia</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Single dose cross-over pilot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of lexaptepid pegol (NOX-H94) cross-over with single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice weekly doses of placebo, 9 total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lexaptepid pegol (NOX-H94)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice weekly doses of lexaptepid pegol (NOX-H94), 9 total</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lexaptepid pegol (NOX-H94)</intervention_name>
    <description>anti-hepcidin L-RNA-aptamer (Spiegelmer)</description>
    <arm_group_label>Single dose cross-over pilot</arm_group_label>
    <arm_group_label>Lexaptepid pegol (NOX-H94)</arm_group_label>
    <other_name>NOX-H94</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Single dose cross-over pilot</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End stage renal disease treated with maintenance hemodialysis.

          -  Anemia : Hb 7 to 11 g/dL.

          -  Functional iron deficiency: Transferrin saturation &lt;30%, Ferritin ≥300 ng/mL.

          -  ESA-hyporesponsiveness with erythropoietin dose ≥12,000 IU/ week.

        Exclusion Criteria:

          -  Treatment with darbepoetin or methoxy-polyethyleneglycol-epoetin.

          -  Uncontrolled / unstable cardiovascular , peripheral arterial or cerebrovascular
             disease.

          -  Congestive heart failure: New York Heart Association Class III or IV.

          -  Unstable angina, myocardial infarction, percutaneous transluminal coronary
             angioplasty/stents, or coronary artery bypass grafting &lt;3 months prior screening.

          -  Any other medical conditions requiring a change in treatment within 4 weeks prior to
             screening or making study participation unadvisable.

          -  History of clinically relevant hemolysis and/or blood loss.

          -  AST, ALT, or bilirubin ≥2.0 times the upper limit of normal.

          -  Known bone marrow fibrosis.

          -  Treatment with i.v. iron &lt;4 weeks prior to screening or during the screening period or
             change in erythropoietin dose during last month.

          -  Any acute or chronic infection, viral or bacterial within 4 weeks prior to screening
             or during the screening period considered as systemic infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Riecke, MD</last_name>
    <role>Study Director</role>
    <affiliation>NOXXON Pharma AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dialysis Unit</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysis Unit</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Swansea</city>
        <state>Wales</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

